poisar

Stocks · News reference

Reported Earlier, Ascendis Pharma To Present New Infant Achondroplasia Trial Data At ESPE 2026

Benzinga Newsdesk

Ascendis Pharma A/S (NASDAQ:ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, the annual congress of the European Society for Paediatric Endocrinology

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ASND
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Benzinga Newsdesk

    Ascendis Announces Week 52 Data From Open-Label Sentinel Cohort Portion Of reACHin Trial Showing Treatment With Once-Weekly TransCon CNP Provided Stabilization Or Improvement In Foramen Magnum Stenosis And Linear Growth Benefits In Infants With Achondroplasia

    – Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment – Treatment with TransCon CNP increased linear growth in the sentinel cohort, with an improvement in

    ASND
  2. Zacks.Com

    How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset

    BioMarin settled a patent dispute with Ascendis Pharma over the achondroplasia drug Yuviwel, converting a competitive threat into a royalty stream. Under the agreement, BioMarin will receive 20% royalties on U.S. Yuviwel sales and 18% in the EU, Brazil, and South Korea through May 2030. While this monetizes competition, BioMarin still faces market pressure from Yuviwel and potential future competitors like BridgeBio's infigratinib.

    BMRNASNDBBIO